Pulse Biosciences (PLSE) just cleared a key regulatory hurdle, with the FDA signing off on its Investigational Device Exemption for the nPulse Cardiac Catheter Ablation System in atrial fibrillation, ...

Pulse Biosciences announced today that the FDA granted investigational device exemption (IDE) for a pulsed field ablation (PFA) study.

Pulse Biosciences today announced a collaboration aimed at using its pulsed field ablation (PFA) technology for thyroid cancer treatment.

As of Friday, December 12, Pulse Biosciences, Inc.’s PLSE share price has surged by 6.69%, which has investors questioning if ...

This single-arm, multicenter, prospective study is designed to demonstrate primary safety and effectiveness of the nsPFA Cardiac Catheter System for the treatment of recurrent drug-resistant ...

The Company’s nsPFA™ System demonstrates the ability to provide cardiac ablation and mapping capabilities with a single catheter in preclinical studies The Company collaborated with CardioNXT to ...

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission “Since joining the Company’s Board last year I have ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

An announcement from Pulse Biosciences ( ($PLSE) ) is now available. On December 9, 2025, Pulse Biosciences announced a research collaboration ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of ...